One phase II clinical trial of 10 patients with NF2-associated VS showed that none of the 9 patients with evaluable disease had objective radiographic or hearing responses.47 However, another phase II trial had more promising results; of 9 patients studied, 5 showed inhibition of tumor growth that resumed within 3–6 months after treatment discontinuation.48 Other targets of this pathway, such as selumetinib, a MEK1/2 inhibitor, are being studied in phase II clinical trials. This evidence concerns the gene NF2 and neoplasm.